Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)].

appendix carcinoid syndrome neuroendocrine neoplasms neuroendocrine tumours radioligand therapy recommendations small intestine somatostatin analogues targeted therapies

Journal

Endokrynologia Polska
ISSN: 2299-8306
Titre abrégé: Endokrynol Pol
Pays: Poland
ID NLM: 0370674

Informations de publication

Date de publication:
2022
Historique:
received: 27 04 2022
accepted: 28 04 2022
entrez: 5 9 2022
pubmed: 6 9 2022
medline: 8 9 2022
Statut: ppublish

Résumé

Updated Polish recommendations for the management of patients with neuroendocrine neoplasms (NENs) of the small intestine (SINENs) and of the appendix (ANENs) are presented here. The small intestine, and especially the ileum, is one of the most common locations for these neoplasms. Most of them are well-differentiated and slow-growing tumours; uncommonly - neuroendocrine carcinomas. Their symptoms may be untypical and their diagnosis may be delayed or accidental. Najczęściej pierwszą manifestacją ANEN jest jego ostre zapalenie. Typical symptoms of carcinoid syndrome occur in approximately 20-30% of SINENs patients with distant metastases. In laboratory diagnostics the assessment of 5-hydroxyindoleacetic acid concentration is helpful in the diagnosis of carcinoid syndrome. The most commonly used imaging methods are ultrasound examination, computed tomography, magnetic resonance imaging, colonoscopy and somatostatin receptor imaging. Histopathological examination is crucial for the proper diagnosis and treatment of patients with SINENs and ANENs. The treatment of choice is a surgical procedure, either radical or palliative. Long-acting somatostatin analogues (SSAs) are essential in the medical treatment of functional and non-functional SINENs. In patients with SINENs, at the stage dissemination with progression during SSAs treatment, with high expression of somatostatin receptors, radioisotope therapy should be considered first followed by targeted therapies - everolimus. After the exhaustion of the above available therapies, chemotherapy may be considered in selected cases. Recommendations for patient monitoring are also presented.

Identifiants

pubmed: 36059174
pii: VM/OJS/J/89814
doi: 10.5603/EP.a2022.0052
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

549-583

Auteurs

Tomasz Bednarczuk (T)

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Anna Zemczak (A)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Marek Bolanowski (M)

Chair and Department of Endocrinology, Diabetes, and Isotope Therapy, Medical University of Wroclaw, Wroclaw, Poland.

Małgorzata Borowska (M)

Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.

Ewa Chmielik (E)

Tumor Pathology Department, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.

Jarosław B Ćwikła (JB)

Department of Cardiology and Internal Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.

Wanda Foltyn (W)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland. wandafoltyn@poczta.onet.pl.

Iwona Gisterek (I)

Chair of Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland.

Daria Handkiewicz-Junak (D)

Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Brench, Gliwice, Poland.

Alicja Hubalewska-Dydejczyk (A)

Chair and Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland.

Michał Jarząb (M)

Breast Unit, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.

Roman Junik (R)

Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Dariusz Kajdaniuk (D)

Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Grzegorz Kamiński (G)

Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland.

Agnieszka Kolasińska-Ćwikła (A)

Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland.

Karolina Kopacz-Wróbel (K)

Department od Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland.

Aldona Kowalska (A)

Department of Endocrinology, Holycross Cancer Centre, Collegium Medicum, Jan Kochanowski University, Kielce, Poland.

Leszek Królicki (L)

Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.

Jolanta Kunikowska (J)

Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.

Katarzyna Kuśnierz (K)

Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland.

Andrzej Lewiński (A)

Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.

Łukasz Liszka (Ł)

Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland.

Magdalena Londzin-Olesik (M)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Bogdan Marek (B)

Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Anna Malczewska (A)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Anna Nasierowska-Guttmejer (A)

Faculty of Medicine, Lazarski University in Warsaw, Warsaw, Poland.

Ewa Nowakowska-Duława (E)

Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland.

Marianne E Pavel (ME)

Department of Medicine 1, Endocrinology and Diabetology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany.

Joanna Pilch-Kowalczyk (J)

Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland.

Jarosław Reguła (J)

Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland.

Violetta Rosiek (V)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Marek Ruchała (M)

Department of Endocrinology, Metabolism and Internal Diseases, Medical University in Poznan, Poznan, Poland.

Grażyna Rydzewska (G)

Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland.

Lucyna Siemińska (L)

Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Anna Sowa-Staszczak (A)

Chair and Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland.

Teresa Starzyńska (T)

Department of Gastroenterology, Medical Pomeranian University in Szczecin, Szczecin, Poland.

Zoran Stojčev (Z)

Department of Oncology and Breast Diseases, Centre of Postgraduate Medical Education, Warsaw, Poland.

Janusz Strzelczyk (J)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Michał Studniarek (M)

Department of Radiology, Medical University of Gdansk, Gdansk, Poland.

Anhelli Syrenicz (A)

Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland.

Marek Szczepkowski (M)

Clinical Department of Colorectal, General and Oncological Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland.

Ewa Wachuła (E)

Department of Clinical Oncology, Gdynia Oncology Centre of the Polish Red Cross Maritime Hospital, Gdynia, Poland.

Wojciech Zajęcki (W)

Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland.

Wojciech Zgliczyński (W)

Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland.

Krzysztof Zieniewicz (K)

Chair and Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

Beata Kos-Kudła (B)

Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH